We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Under the first agreement, Celgene will make an upfront cash payment of $80 million to Kyn, whilst also making an equity investment in the company. In return, Celgene will gain exclusive options to globally license Kyn's kynurenine-degrading enzyme and ar